Table 3.
Univariate and multivariate analyses of overall survival in high-expression of hsa-mir-3923 in patients with GC.
| Parameters | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value | |
| Age, years (≤55 > 55) | 4.965 | 1.003–1.052 | 0.026 | |||
| Gender (Female & Male) | 4.649 | 0.356–0.952 | 0.031 | |||
| Race (Asian & Black & White) | 0.536 | 0.832–1.495 | 0.464 | 1.714 | 0.872–2.13 | 0.175 |
| Grade (G1 & G2 & G3 & G4) | 0.365 | 0.727–1.827 | 0.546 | 1.121 | 0.724–2.952 | 0.29 |
| Stage (Stage I & II & III & IV) | 1.478 | 0.769–2.501 | 0.078 | 1.796 | 1.14–2.122 | 0.005 |
| T stage (T1 & T2 & T3 & T4) | 1.843 | 0.707–2.525 | 0.191 | 2.165 | 1.269–3.120 | 0.057 |
| M stage (M0 & M1) | 0.016 | 0.31–3.795 | 0.898 | |||
| N stage (N0 & N1/2/3) | 0.001 | 0.738–1.344 | 0.979 | |||
| Hsa-mir-3923 | 0.332 | 0.561–1.371 | 0.564 | |||
Bold values indicate statistically significant, P <0.05.